Schedule 13G ownership disclosure

Monte Rosa Therapeutics Inc

Common Stock, par value $0.0001 per share · CUSIP: 61225M102

Event date: 2024-05-16

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Adam Goulburn

    Shares: 4,757,563 · Class: 7.7%

  • Zavain Dar

    Shares: 4,757,563 · Class: 7.7%

  • Nan Li

    Shares: 4,757,563 · Class: 7.7%

  • Dimension Management, L.P.

    Shares: 4,757,563 · Class: 7.7%

  • Dimension Capital I GP, LLC

    Shares: 4,757,563 · Class: 7.7%

  • Dimension Management GP, LLC

    Shares: 4,757,563 · Class: 7.7%

  • Dimension Capital I, L.P.

    Shares: 4,757,563 · Class: 7.7%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001012975-25-000601
Form type
SCHEDULE 13G
Filer
Dimension Capital I, L.P.
CIK
CIK 1939538
Filed
Oct 03, 2025
Reporting period
May 16, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub